The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, polymorphisms in various cytochrome P450 (CYP450) enzymes and specific human leukocyte antigen alleles involved in statin metabolism may contribute to an increased risk of liver injury and rhabdomyolysis.14–16”
From Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge (2025) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
Research works printed but not linked: 29
- Saku K, Zhang B, Noda K, Investigators PT. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011;75(6):1493–505. · DOI
- Ooba N, Sato T, Wakana A, Orii T, Kitamura M, Kokan A, Kurata H, Shimodozono Y, Matsui K, Yoshida H, et al A prospective stratified case-cohort study on statins and multiple adverse events in Japan. PLoS One. 2014;9(5):e96919. · DOI
- Liu Y, Cheng Z, Ding L, Fang F, Cheng KA, Fang Q, Shi GP. Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther. 2010;48(12):798–802. · DOI
- Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2007;82(6):726–33. · DOI · Paper page
- Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, Schaeffeler E. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 2013;5(1):1. · DOI · Paper page
- Lee YJ, Lee MG, Lim LA, Jang SB, Chung JY. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther. 2010;48(1):36–45. · DOI
- Yasar U, Sain-Guven G, Yardimci Y, Kilicarslan A, Babaoglu MO, Bozkurt A. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients. Basic Clin Pharmacol Toxicol. 2011;109(2):73–7. · doi:10.1111/j.1742-7843.2011.00687.x
- Stormo C, Bogsrud MP, Hermann M, Asberg A, Piehler AP, Retterstol K, Kringen MK. UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013;17(4):233–7. · DOI
- Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther. 2010;87(1):65–73. · DOI
- Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica. 2008;38(9):1240–51. · DOI
- Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. JACC Cardiovasc Interv. 2013;6(2):169–79. · DOI
- Kokudai M, Inui N, Takeuchi K, Sakaeda T, Kagawa Y, Watanabe H. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers. J Clin Pharmacol. 2009;49(5):568–73. · DOI
- Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009;86(2):197–203. · DOI · Paper page
- Black AE, Hayes RN, Roth BD, Woo P, Woolf TF. Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos. 1999;27(8):916–23.
- Rosales A, Alvear M, Cuevas A, Saavedra N, Zambrano T, Salazar LA. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Clin Chim Acta. 2012;413(3-4):495–501. · doi:10.1016/j.cca.2011.11.003
- Poduri A, Khullar M, Bahl A, Sehrawat BS, Sharma Y, Talwar KK. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol. 2010;29(10):629–37. · DOI
- Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther. 2008;84(4):457–61. · DOI
- Ishikawa T, Wakabayashi-Nakao K, Nakagawa H. Methods to examine the impact of nonsynonymous SNPs on protein degradation and function of human ABC transporter. Methods Mol Biol. 2013;1015:225–50. · DOI
- Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet. 2001;46(8):471–7. · DOI · Paper page
- Sakurai A, Onishi Y, Hirano H, Seigneuret M, Obanayama K, Kim G, Liew EL, Sakaeda T, Yoshiura K, Niikawa N, et al. Quantitative structure--activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry (Mosc). 2007;46(26):7678–93. · DOI
- Schaefer M, Roots I, Gerloff T. In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet Genomics. 2006;16(12):855–61. · DOI
- Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, Koyama T, Okamura N, Miki I, Tamura T, et al. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet. 2006;21(2):126–32. · doi:10.2133/dmpk.21.126
- Gandelman K, Fung GL, Messig M, Laskey R. Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies. Am J Ther. 2012;19(3):164–73. · DOI
- Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One. 2011;6(12):e28124. · DOI
- Chang CH, Kusama M, Ono S, Sugiyama Y, Orii T, Akazawa M. Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information. BMJ open 2013;3(4):e002040. · DOI
- Hermann M, Bogsrud MP, Molden E, Asberg A, Mohebi BU, Ose L, Retterstol K. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther. 2006;79(6):532–9. · DOI
- Goosen TC, Bauman JN, Davis JA, Yu C, Hurst SI, Williams JA, Loi CM. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007;35(8):1315–24. · DOI
- Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ. 1998;316(7140):1295–8. · DOI · Paper page
- Kaniwa N, Saito Y. Pharmacogenomics of severe cutaneous adverse reactions. Pharmacogenomics. 2013;14(6):595–8. · DOI
Cited by
Genetic risk factors in the development of idiosyncratic drug-induced liver injury
Stephens, C., Lucena, M. I., & Andrade, R. J. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1854726 · Cited by 32
Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge
Singh, H., Khalaf, A., Kunkle, B. F., Gholami, S., Lewis, J. H., & Rangnekar, A. S. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001570 · Cited by 3
Metadata
- Authors
- Fukunaga, K., Nakagawa, H., Ishikawa, T., Kubo, M., & Mushiroda, T.
- Venue
- BMC Genetics
- Published
- 2016-06-13
- Volume
- 17
- Issue
- 1
- ISSN
- 1471-2156
- PMC
- PMC4906899
- Cited by
- 35
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. https://app.cochat.ai/papers/10.1186/s12863-016-0390-5
- The paper
- Fukunaga, K., Nakagawa, H., Ishikawa, T., Kubo, M., & Mushiroda, T. (2016). ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC Genetics. https://doi.org/10.1186/s12863-016-0390-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.